OCGN

Ocugen

Healthcare Biotechnology NASDAQ

About the company

Ocugen Inc is at the forefront of the biopharmaceutical industry, dedicated to transforming the lives of individuals suffering from various forms of blindness. With a strong focus on discovering, developing, and commercializing gene therapies, this clinical-stage company is paving the way for groundbreaking treatments that hold the promise of curing previously incurable diseases. One of the key pillars of Ocugen's research and development efforts lies in their innovative gene therapy platform. This platform is designed to combat a wide range of retinal diseases with a single drug, offering a potential one-to-many treatment approach. By targeting the underlying genetic causes of these diseases, Ocugen is aiming to revolutionize the way blindness is treated, providing new hope and improved quality of life for countless patients. Among the diseases in Ocugen's sights are wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy. These conditions, which often result in severe vision loss or blindness, currently have limited treatment options. Ocugen's novel biologic product candidate aims to address this underserved patient population, offering more effective therapies that can potentially halt or reverse the progression of these debilitating diseases. In addition to their focus on ocular gene therapies, Ocugen has also taken on the global battle against COVID-19. The company is actively co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the United States and Canadian markets. As the pandemic continues to impact millions of lives worldwide, Ocugen recognizes the urgent need for effective vaccines, and their collaboration with Bharat Biotech exemplifies their commitment to saving lives and ensuring global public health. With their dedication to pioneering gene therapies and their contribution to the fight against COVID-19, Ocugen Inc is making significant strides in the field of biopharmaceuticals. Their innovative approach, coupled with their commitment to improving patient outcomes, has positioned them as leaders in the pursuit of novel treatments for blindness and infectious diseases. As they continue to advance their research and development efforts, Ocugen is poised to make a lasting impact on the lives of countless individuals around the world.

Website: https://www.ocugen.com

Data updated: June 2, 2026

Sector comparison

We compare this company with the typical (middle) company in the same industry to show how it looks against similar businesses. This is information, not a recommendation.

Healthcare · 1345 peers in sector

Metric OCGN Sector median Vs. industry
P/E - 20.13
EPS -0.24 USD -1.14 USD ↑ Above average
Dividend yield 0.00% 0.00%
Profit margin 0.00% 0.00%
ROE -6.60% -58.89% ↓ Below average

Higher and lower here are only a comparison with the typical company in the industry — a higher or lower value on its own does not mean better or worse.

Financial statements & historical data

Income statements, balance sheets, cash flow, earnings and dividend history are available for registered users

Sign up for free

AI Summary

AI-generated company analysis is available for registered users.

Sign up for free

Where does this data come from?

Frequently Asked Questions

What is Ocugen?
Ocugen Inc is at the forefront of the biopharmaceutical industry, dedicated to transforming the lives of individuals suffering from various forms of blindness. With a strong focus on discovering, developing, and commercializing gene therapies, this clinical-stage company is paving the way for groundbreaking treatments that hold the promise of curing previously incurable diseases. One of the key pillars of Ocugen's research and development efforts lies in their innovative gene therapy platform. This platform is designed to combat a wide range of retinal diseases with a single drug, offering a potential one-to-many treatment approach. By targeting the underlying genetic causes of these diseases, Ocugen is aiming to revolutionize the way blindness is treated, providing new hope and improved quality of life for countless patients. Among the diseases in Ocugen's sights are wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy. These conditions, which often result in severe vision loss or blindness, currently have limited treatment options. Ocugen's novel biologic product candidate aims to address this underserved patient population, offering more effective therapies that can potentially halt or reverse the progression of these debilitating diseases. In addition to their focus on ocular gene therapies, Ocugen has also taken on the global battle against COVID-19. The company is actively co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the United States and Canadian markets. As the pandemic continues to impact millions of lives worldwide, Ocugen recognizes the urgent need for effective vaccines, and their collaboration with Bharat Biotech exemplifies their commitment to saving lives and ensuring global public health. With their dedication to pioneering gene therapies and their contribution to the fight against COVID-19, Ocugen Inc is making significant strides in the field of biopharmaceuticals. Their innovative approach, coupled with their commitment to improving patient outcomes, has positioned them as leaders in the pursuit of novel treatments for blindness and infectious diseases. As they continue to advance their research and development efforts, Ocugen is poised to make a lasting impact on the lives of countless individuals around the world.
How big is Ocugen?
The market capitalization of Ocugen — the combined value of all its shares — is 463.8 M USD. The higher the market cap, the larger the company. (as of 2026-06-02)
Does Ocugen pay dividends?
The dividend yield of Ocugen is 0.00% — it shows the annual dividend relative to the share price. This is information, not a recommendation. (as of 2026-06-02)
What sector does Ocugen belong to?
Ocugen operates in the Healthcare sector, industry: Biotechnology.

What do you gain?

With Ecrumen you gain full control over your investments and assets!

All your assets
Stock market investments, real estate, bonds. Be aware of what you have in your portfolio!
AI at the service of your investments
Analyze and optimize your investments using the latest technologies. Sentiments, analyses, tips, reports. Always with up-to-date data!
A community eager to help
Find a place with people similar to you. Share your opinions, see how others manage their investments. Get help with the problems that bother you!
What do you gain?

Want to stay up to date?

Subscribe to our newsletter to stay up to date with Ecrumena news and market information. No spam, unsubscribe in one click.

For more information, please refer to our terms of use.

0/120